

Appendix 1: 2891 de novo patient outcomes from study entry												
	Overall				Intensive Timing Induction Therapy				Standard Timing Induction Therapy			
	6vr Survival		6vr Event-Free		6vr Survival		6vr Event-Free Survival		6vr Survival		6vr Event-Free Survival	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	48% (4%)	0.003	36% (4%)	0.077	49% (5%)	0.296	40% (5%)	0.971	44% (7%)	0.001	29% (7%)	0.028
Black	34% (10%)	0.007	25% (9%)	0.044	43% (14%)	0.377	40% (14%)	0.893	23% (13%)	0.005	9% (9%)	0.026
Hispanic	37% (9%)	0.016	33% (9%)	0.191	45% (12%)	0.286	42% (12%)	0.861	22% (13%)	0.011	17% (12%)	0.084
Asian	54% (21%)	0.847	44% (20%)	0.503	54% (26%)	0.676	44% (25%)	0.634	52% (35%)	0.860	44% (33%)	0.553
Overall												
	6 yr Survival				6 yr Event-Free Survival							
	Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	57% (10%)	0.199	48% (9%)	0.280	67% (9%)	0.057	43% (10%)	0.524	39% (9%)	0.562	55% (9%)	0.223
Black	32% (19%)	0.038	38% (21%)	0.205	50% (41%)	0.203	19% (15%)	0.044	35% (20%)	0.459	38% (34%)	0.092
Hispanic	57% (21%)	0.981	35% (24%)	0.344	54% (20%)	0.193	49% (21%)	0.608	37% (23%)	0.605	50% (20%)	0.647
Asian	50% (32%)	0.792	100% (0%)	0.204	60% (44%)	0.197	50% (32%)	0.574	67% (54%)	0.420	60% (44%)	0.522
Intensive Timing Induction Therapy												
	6 yr Survival				6 yr Event-Free Survival							
	Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	56% (12%)	0.714	52% (11%)	0.761	70% (10%)	0.387	45% (12%)	0.849	42% (11%)	0.602	59% (11%)	0.720
Black	31% (26%)	0.160	50% (29%)	0.765	67% (54%)	0.957	31% (26%)	0.369	50% (29%)	0.807	50% (50%)	0.576
Hispanic	61% (23%)	0.737	48% (28%)	0.472	60% (25%)	0.424	56% (23%)	0.603	49% (27%)	0.995	60% (25%)	0.985
Asian	57% (37%)	0.738	100% (0%)	0.252	50% (71%)	0.302	57% (37%)	0.432	100% (0%)	0.191	50% (71%)	0.571
Standard Timing Induction Therapy												
	6 yr Survival				6 yr Event-Free Survival							
	Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	58% (16%)	0.088	34% (16%)	0.436	62% (16%)	0.151	38% (15%)	0.160	29% (15%)	0.230	46% (16%)	0.382
Black	34% (27%)	0.113	24% (28%)	0.381	33% (54%)	0.125	8% (15%)	0.081	18% (23%)	0.402	25% (43%)	0.179
Hispanic	40% (44%)	0.459	0% (0%)	0.847	45% (30%)	0.358	20% (36%)	0.883	0% (0%)	0.384	36% (29%)	0.663
Asian	33% (54%)	0.335	100% (0%)	0.697	67% (54%)	0.636	33% (54%)	0.744	0% (0%)	0.391	67% (54%)	0.983

Appendix 1: 2891 de novo patient outcomes from end of two courses

	Overall						Intensive Timing Induction Therapy						Standard Timing Induction Therapy					
	6yr Survival		6yr Disease-Free		6yr Relapse-Free		6yr Survival		6yr Disease-Free		6yr Relapse-Free		6yr Survival		6yr Disease-Free		6yr Relapse-Free	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	59% (5%)	0.009	47% (5%)	0.105	52% (5%)	0.248	60% (6%)	0.317	50% (6%)	0.955	54% (6%)	0.904	56% (9%)	0.008	40% (9%)	0.028	45% (9%)	0.106
Black	43% (12%)	0.004	33% (11%)	0.012	39% (12%)	0.042	53% (17%)	0.411	51% (16%)	0.997	54% (17%)	0.928	29% (17%)	0.003	13% (12%)	0.002	18% (15%)	0.015
Hispanic	50% (12%)	0.137	46% (12%)	0.772	52% (12%)	0.856	56% (14%)	0.364	54% (14%)	0.934	60% (14%)	0.811	37% (20%)	0.226	29% (19%)	0.595	36% (20%)	0.582
Asian	61% (22%)	0.775	42% (23%)	0.931	49% (26%)	0.727	62% (27%)	0.936	50% (27%)	0.999	54% (28%)	0.968	58% (37%)	0.650	33% (36%)	0.974	46% (45%)	0.536
	Overall																	
	6 yr Survival				6 yr Disease-Free Survival				6 yr Relapse-Free Survival									
	Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	58% (10%)	0.149	49% (9%)	0.414	68% (9%)	0.078	44% (10%)	0.436	41% (9%)	0.608	56% (9%)	0.299	46% (10%)	0.427	44% (9%)	0.882	67% (9%)	0.442
Black	32% (19%)	0.028	42% (22%)	0.320	60% (44%)	0.410	19% (15%)	0.033	38% (21%)	0.523	43% (37%)	0.235	20% (16%)	0.023	46% (23%)	0.933	71% (34%)	0.997
Hispanic	57% (21%)	0.907	36% (25%)	0.416	54% (20%)	0.190	49% (21%)	0.665	39% (24%)	0.597	50% (20%)	0.650	51% (21%)	0.683	42% (26%)	0.628	61% (19%)	0.466
Asian	50% (32%)	0.690	100% (0%)	0.208	60% (44%)	0.189	50% (32%)	0.637	67% (54%)	0.437	30% (48%)	0.506	56% (33%)	0.485	67% (54%)	0.497	40% (59%)	0.588
	Intensive Timing Induction Therapy																	
	6 yr Survival				6 yr Disease-Free Survival				6 yr Relapse-Free Survival									
	Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	57% (12%)	0.606	52% (11%)	0.962	70% (11%)	0.575	46% (13%)	0.938	44% (11%)	0.462	59% (11%)	0.983	50% (13%)	0.992	47% (11%)	0.338	69% (11%)	0.619
Black	31% (26%)	0.133	55% (30%)	0.992	100% (0%)	0.340	31% (26%)	0.319	55% (30%)	0.623	67% (54%)	0.772	33% (27%)	0.326	61% (31%)	0.491	67% (54%)	0.954
Hispanic	61% (23%)	0.806	50% (29%)	0.644	60% (25%)	0.432	56% (23%)	0.654	52% (29%)	0.938	60% (25%)	0.993	59% (24%)	0.660	59% (29%)	0.815	67% (24%)	0.760
Asian	57% (37%)	0.831	100% (0%)	0.257	50% (71%)	0.303	57% (37%)	0.465	100% (0%)	0.201	50% (71%)	0.571	57% (37%)	0.592	100% (0%)	0.220	50% (71%)	0.374
	Standard Timing Induction Therapy																	
	6 yr Survival				6 yr Disease-Free Survival				6 yr Relapse-Free Survival									
	Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT		Chemo.		Auto BMT		Allo BMT	
	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value	% (2SE)	p-value
White	59% (16%)	0.079	38% (17%)	0.430	64% (16%)	0.144	38% (16%)	0.143	31% (16%)	0.213	48% (16%)	0.378	35% (16%)	0.163	34% (17%)	0.315	62% (17%)	0.710
Black	34% (27%)	0.110	30% (29%)	0.409	33% (54%)	0.120	8% (14%)	0.070	20% (25%)	0.348	25% (43%)	0.177	8% (15%)	0.053	25% (31%)	0.653	75% (43%)	0.859
Hispanic	40% (44%)	0.426	0% (0%)	0.724	45% (30%)	0.358	20% (36%)	0.879	0% (0%)	0.346	36% (29%)	0.683	20% (36%)	0.826	0% (0%)	0.267	52% (31%)	0.566
Asian	33% (54%)	0.302	100% (0%)	0.595	67% (54%)	0.596	33% (54%)	0.735	0% (0%)	0.650	33% (54%)	0.928	50% (71%)	0.704	0% (0%)	0.545	50% (71%)	0.934

Relapse free survival (RFS) events were defined as leukemia relapse, secondary malignancy, or death due to progressive disease. Non-progressive disease death was censored for RFS analyses.